Digital Better analytics leads to fewer regulator questions Stronger data analytics is cutting the number of questions regulators ask about intensified processes.
News Sandoz says it is entering "golden decade" in biosimilars Sandoz said today it intends to double net sales between 2025 and 2035, fuelled by an acceleration in biosimilar medicine development.
News Sandoz adds 10 biosimilars through $322m Henlius deal Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.
Patients Sponsored 12 Questions with Kim Innes Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.
News Sandoz will pay another $480m to settle US antitrust suits Sandoz has reached a settlement in the US that, if approved, could lay to rest years of litigation over price-fixing of generic medicines.
R&D Sponsored What European Commission marketing authorisation of a teripa... Biosimilars can help support broader patient access while contributing to the long-term sustainability of healthcare systems.
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
